We have shown that internalizing anti-HER2 212Pb-mAbs targets antigen expressing xenografts and are more efficient per Gy than non-internalizing anti-CEA 212Pb-mAbs in reducing and eradicating tumor growth. Here, ERBB2 is linked to neoplasm.